Cavernostomy x Resection for Pulmonary Aspergilloma: A 32-Year History

Jorge MS Cesar*, Jose S Resende, Nilson F Amaral, Carla MS Alves, Alyne F Vilhena and Frederico L Silva

Abstract

Background: The most adequate surgical technique for the treatment of pulmonary aspergilloma is still controversial. This study compared two groups of patients submitted to cavernostomy and pulmonary parenchyma resection.

Methods: Cases of pulmonary aspergilloma operated upon between 1979 and 2010 were analyzed retrospectively. Group 1 consisted of patients submitted to cavernostomy and group 2 of patients submitted to pulmonary parenchyma resection. The following variables were compared between groups: gender, age, number of hospitalizations, pre- and postoperative length of hospital stay, time of follow-up, location and type of aspergilloma, preoperative symptoms, underlying disease, type of fungus, preoperative pulmonary function, postoperative complications, patient progression, and associated diseases.

Results: A total of 208 patients with pulmonary aspergilloma were studied (111 in group 1 and 97 in group 2). Group 1 was older than group 2. The number of hospitalizations, length of hospital stay and time of follow-up were higher in group 1. Hemoptysis was the most frequent preoperative symptom in group 1. Preoperative respiratory malfunction was more severe in group 1. Hemorrhagic complications and recurrence were more frequent in group 1 and infectious complications and residual pleural space were more common in group 2. Postoperative dyspnea was more frequent in group 2. Patient progression was similar in the two groups. No difference in the other factors was observed between groups.

Conclusions: Older patients with severe preoperative respiratory malfunction and peripheral pulmonary aspergilloma should be submitted to cavernostomy. The remaining patients can be treated by pulmonary resection.

Keywords: Fungal infection, Haemoptysis, Lung surgery, Surgical management, Thoracic surgery, Tuberculosis

Introduction

Controversies still exist regarding the most adequate surgical technique for the treatment of pulmonary aspergilloma despite decades of investigation. Some authors defend surgical treatment in all cases, even when asymptomatic, due to the risk of hemoptysis [1-11]. Other investigators indicate surgery only for symptomatic cases in view of the high rates of surgical morbidity and mortality [2,5,12-21]. Cavernostomy has only been indicated for the treatment of severely ill patients [5,17] whose clinical condition does not permit resection of the pulmonary parenchyma, or in cases of complex aspergillomas [1,5,6,18,22,23]. In contrast, Henderson and Pearson [16], Sagawa and colleagues [24] and Grima and colleagues [25] reported that cavernostomy is a simple and effective procedure which is free of complications and can be applied when more extensive surgery is contraindicated.

The present study evaluated factors associated with cavernostomy and pulmonary parenchyma resection, whose results will contribute to the choice of treatment of pulmonary aspergilloma.

Patients and Methods

A retrospective study was conducted in which the records and radiologic exams of patients with pulmonary...
aspergilloma treated at the Julia Kubitschek Hospital between 1979 and 2010 were analyzed. The diagnosis of pulmonary aspergilloma was made based on clinical and radiologic examination, surgical findings, and isolation of the fungus. All cases were submitted to surgical treatment, irrespective of the presence of symptoms. The choice of the surgical technique was based on the location of the aspergilloma, pulmonary function, clinical condition of the patient, and preference of the surgeon.

The cases were divided into two groups: group 1 consisted of patients submitted to cavernostomy and group 2 of patients submitted to pulmonary parenchyma resection. The following variables were compared between groups: gender, age, number of hospitalizations, pre- and postoperative length of hospital stay, time of follow-up, location and type of aspergilloma, preoperative symptoms, underlying disease, type of fungus, preoperative pulmonary function, postoperative complications, patient progression, and associated diseases.

Peri- and postoperative bleeding, retained intrathoracic blood clots, and hemoptysis were classified as hemorrhagic complications. Infectious complications were septic shock, pleural empyema, and pulmonary infection. Pulmonary function was evaluated according to the classification of the American Thoracic Society [26]. Patients presenting recurrence and sequelae associated with treatment complications were classified as not cured. Cavernostomy was performed according to a previously described technique [18,27]. The fungus ball was localized by non-guided puncture during surgery. Two fragments of the costal arch were resected over the pulmonary cavern and a pneumotomy was performed over the lesion and kept opened with no suture. The fungus ball was removed with a spoon. The cavern was packed with gauze containing no antifungal substance. The gauze was removed after 24 h during cavernoscopy [27]. The cavity was left to close spontaneously and myoplasty was only performed when the cavity remained open for more than 90 days after surgery.

The Student t-test, chi-square test and Fisher’s exact test were used for statistical analysis, with the level of significance set at 95%.

Results
A total of 208 patients with pulmonary aspergilloma were studied, including 111 in group 1 and 97 in group 2. Group 1 was older than group 2, with mean ages of 42.13 and 37.67 years, respectively ($p = 0.013$). There were no gender differences between the two groups. Patients of group 1 were more frequently hospitalized (Table 1) and remained in the hospital for a longer period of time (Table 2) when compared to group 2. Follow-up was longer for patients of group 1 (1482.5 days) than group 2 (582.4 days) ($p < 0.001$).

Ten (9%) patients of group 1 required pulmonary parenchyma resection after cavernostomy because of recurrence. In group 2, lobectomy was performed on 53 patients (54.6%), pneumonectomy on 28 (28.9%), and segmentectomy on five (5.2%) (Table 3). There was no difference in the location (Table 4) or type of aspergilloma (Table 5) between the two groups.

The frequency of preoperative symptoms was similar in groups 1 and 2, except for hemoptysis which was observed in 106 (95.5%) patients of group 1 and in 57 (58.8%) of group 2 (Table 6). There was no difference in the underlying disease between groups 1 and 2 (Table 7). Table 8 shows the type of fungus isolated from the aspergilloma.

Severe respiratory malfunction was more frequent in group 1 (n = 16, 27.1%) than in group 2 (n = 5, 7.7%). Normal respiratory function was observed in 23 (39%) patients of group 1 and in 34 (52.3%) of group 2 ($p = 0.017$).

Ten (10.3%) patients of group 2 and none of group 1 presented residual pleural space ($p < 0.001$). Dyspnea was more frequent in group 2 (n = 11, 11.3%) than in group 1 (n = 2, 1.8%) ($p = 0.005$). The incidence of fistulae did not differ between group 1 (n = 8, 7.2%) and group 2 (n = 7, 7.2%) ($p = 0.602$). Hemorrhagic complications were more frequent in group 1 (n = 50, 45%) than in group 2 (n = 12, 12.4%) ($p < 0.001$). Infectious complications were identified in eight (7.2%) patients of group 1 and in 24 (24.7%) of group 2 ($p < 0.001$). Recurrence was only observed in group 1 (n = 9, 8.1%) ($p = 0.003$).

Patient progression was similar in the two groups: 52 (67.5%) patients in group 1 were cured, 10 (13.0%) were not cured, and 15 (19.5%) died. In group 2, 56 (73.7%) patients were cured, 10 (13.2%) were not cured, and 10 (13.2%) died ($p = 0.589$).

The two groups were similar in terms of associated diseases: cardiovascular diseases were present in 14 (12.6%) patients of group 1 and in nine (9.3%) of group 2 ($p = 0.295$); diabetes in six (5.4%) patients of group 1 and in six (6.2%) of group 2 ($p = 0.520$); respiratory diseases in 15 (13.5%) patients of group 1 and in six (6.2%) of group 2 ($p = 0.063$), and other diseases in 21 (18.9%) patients of group 1 and in 13 (13.4%) of group 2 ($p = 0.188$).

Comment
Patients of group 1 presented a longer mean hospital stay and a larger number of hospitalizations than those of group 2. This difference might be explained by the fact that most cavernostomies were performed at the beginning of the historical series when treatment was still institutional, including long periods of hospitalization. Another explanation is the larger number of patients with severe respiratory malfunction and of older patients.
in group 1. Kim and colleagues [28], Sagan and colleagues [11] and Sagawa colleagues [24] identified old age as a risk factor for postoperative complications. Oakley and colleagues [5] reported a mean length of hospital stay of 11 days for patients submitted to resection and of 16 days for those undergoing cavernostomy. The time of follow-up was significantly longer in group 1, probably because of the prolonged hospital stay of these patients. Henderson and colleagues [15] followed up patients for 2 to 48 months after surgery, with a mean of 20 months.

In the study of Oakley and colleagues [5], the main type of resection was right upper lobectomy, followed by left upper lobectomy. Right upper lobectomy was also the most common surgical procedure in other series [1,2,5,9,15,28]. Some investigators [5,18] recommend pneumonectomy to be avoided whenever possible because of postoperative complications. In the present series, lobectomy was the main type of resection. The large number of pneumonectomies (n = 28, 28.9%) and the small number of segmentectomies (n = 5, 5.2%) might be attributed to the predominance of complex aspergillomas and “destroyed lungs” due to tuberculosis sequelae.

In groups 1 and 2, aspergillomas were mainly found in the upper pulmonary lobes, with both lobes being affected in seven patients (3.4%). In the study of Chen and colleagues [2], most aspergillomas were located in the upper lobe (31 on the right and 28 on the left), a finding also reported in other studies [1,6,17,29,30]. This distribution might be associated with the predominance of tuberculosis sequelae, hypoperfusion, or hypoventilation in the upper pulmonary segments [29]. Jewkes and colleagues [17] reported the presence of more than one aspergilloma in 19 (22%) of 85 patients, including 12 bilateral cases. Complex aspergillomas were observed in 95 (89.6%) patients of group 1 and in 88 (94.6%) of group 2, with no significant difference between groups. A higher frequency of complex aspergillomas has also been reported in other series [1,2,11,22,23,28].

Hemoptysis was the most frequent preoperative symptom in groups 1 and 2, and was observed in 163 patients (78.4%). Similar findings have been reported by other investigators [1,2,4,5,7-9,14,23,29,31,32]. However, hemoptysis was more frequent in group 1 than in group 2. This finding might be explained by the fact that most asymptomatic patients were allocated to group 2. In the study of Henderson and colleagues [15], cough with expectoration was the most frequent symptom, affecting 20 patients (83%). Hemoptysis was observed in 11 patients (46%). In the present series, the frequency of the other preoperative symptoms was similar in the two groups. Dyspnea and cough were the second most frequent symptoms after hemoptysis, in agreement with other studies [2,12,30-33].

Tuberculosis sequelae, but not active disease, were the underlying disease in 188 (93.1%) patients, with no difference between groups 1 and 2. Other studies also identified tuberculosis as the underlying disease [4,7-9,12,17,21,28,32]. Interestingly, sarcoidosis was not detected in any patient as the underlying disease, in contrast to other reports [2,33]. Tuberculosis and sarcoidosis were the most frequent underlying diseases in the studies of Battaglini and colleagues [1] and Nucci and colleagues [20]. The other underlying diseases cited by these authors have also been observed in our series, i.e., bronchiectasis, congenital cyst, and pulmonary abscess.

Aspergillus fumigatus was the fungus most frequently isolated from the pulmonary cavities of 37 (48.1%) patients in group 1 and Aspergillus sp was the most frequent fungus in group 2, detected in 29 patients (38.7%). Henderson and Pearson [16] found A. fumigatus to be the most common species in cultures of fungus balls.

Jewkes and colleagues [17] and Oakley and colleagues [5] used the presence of diffuse pulmonary disease and

| Table 1 Number of Hospitalizations |
|-----------------------------------|
| Procedure                          | Number of hospitalizationsa |
|-----------------------------------|----------------------------|
|                                   | Mean | Median | SD  | Minimum | Maximum | 25th Percentile | 75th Percentile |
|-----------------------------------|------|--------|-----|---------|---------|----------------|----------------|
| Cavernostomy (n = 111)            | 1.8  | 1.0    | 1.2 | 1.0     | 6.0     | 1.0            | 2.0            |
| Resection (n = 97)                | 1.4  | 1.0    | 0.9 | 1.0     | 7.0     | 1.0            | 1.0            |

SD: standard deviation.

a p = 0.004 (t-test for equality of means, Levene’s test for equality of variances).

| Table 2 Length of Hospital Stay |
|---------------------------------|
| Procedure                       | Length of hospital stay (days)a |
|---------------------------------|---------------------------------|
|                                 | Mean  | Median | SD  | Minimum | Maximum | 25th Percentile | 75th Percentile |
|---------------------------------|-------|--------|-----|---------|---------|----------------|----------------|
| Cavernostomy (n = 111)          | 128.8 | 90.0   | 114.0 | 3.0     | 540.0   | 41.0           | 200.0          |
| Resection (n = 97)              | 59.3  | 30.0   | 67.9 | 7.0     | 450.0   | 16.0           | 71.0           |

SD: standard deviation.

a p < 0.001 (t-test for equality of means, Levene’s test for equality of variances).
poor pulmonary function (forced expiratory volume in the first second (FEV₁) < 1.34 liters and forced vital capacity (FVC) < 2.0 liters) as criteria for the indication of cavernostomy for the treatment of pulmonary aspergilloma. Cut-off values of mean predicted FVC of 78.5% and mean predicted FEV₁ of 65% have been reported by Chen and colleagues [2] for the assessment of preoperative pulmonary function. In the present series, poor pulmonary function was observed in 16 (27.1%) patients of group 1 and in only five (7.7%) of group 2. The severity of preoperative respiratory malfunction may have been one criterion for the selection of patients for cavernostomy.

Hemorrhagic complications and recurrence were more frequent in group 1, and infectious complications and residual cavities were more common in group 2. Bleeding was the main postoperative complication in the study of Chen and colleagues [2]. According to Butz and colleagues [14], a post-resection pleural space is the most frequent complication after parenchyma resection for the treatment of aspergilloma. This residual pleural space may have been the cause of empyemas observed in group 2, especially when associated with a bronchopleural fistula as reported by other investigators [1,2,5,9,15,18,20,23,28]. In the present study, the incidence of fistulae was similar in the two groups, but the association of fistula, residual pleural space and tuberculosis sequelae was only observed in group 2. In addition, a fistula was present in seven (24%) of the 24 patients of group 2 with infectious complications, a fact explaining the higher incidence of infectious complications in this group. No fungal organism or bacterial superinfection was detected in any of the patients with pleural empyemas. The patients received no antifungal drugs, oral or intravenous triazoles [34] or amphotericin B as recommended by Sagan and colleagues [30]. No postoperative fungal dissemination was observed. A residual pleural space was a frequent postoperative finding in group 2 (n = 10, 10.3%), especially among patients with tuberculosis sequelae as the underlying disease. The latter has been considered to be a predisposing factor for complications and increased mortality [1,5,14]. Dyspnea was more frequent in group 2 despite better preoperative respiratory function. This finding can be explained by the fact that patients with diffuse pulmonary tuberculosis sequelae undergoing resection have no respiratory function reserve.

None of the present patients was submitted to arteriography or embolization for the treatment of significant hemoptysis because of the lack of a hemodynamic center in our hospital. However, embolization and CT-guided catheter drainage represent therapeutic alternatives for patients with pulmonary aspergilloma whose clinical condition does not permit surgery [35].

No significant difference in mortality was observed between groups 1 and 2. Mortality rates ranging from 1.1% to 44% have been reported in the literature [1,2,9,10,15,18,20,28]. This variation in mortality can be explained by the fact that surgery is performed on symptomatic and asymptomatic patients, with mortality being lower in the latter [18]. In the study of Jewkes and colleagues [17], three (7%) of 41 patients submitted to resection and four (44%) of nine patients submitted to cavernostomy with no clinical condition for major surgery died after the procedure. This difference was probably due to the fact that cavernostomy was reserved for more severely ill patients. Solit and colleagues [21] reported no elevated morbidity or mortality. Recent studies [2,4,5,8,10] have shown a significant reduction in surgical morbidity and mortality, encouraging a more frequent indication of surgery. The evolution of patients in group 1 might be attributed to the selection of patients with more severe respiratory malfunction and of older patients. A prospective study could help clarify this issue. Both groups had their

### Table 3 Pulmonary Parenchyma Resection

| Procedure | Frequency | Valid percent |
|-----------|-----------|---------------|
| Bilobectomy | 6 | 6.2 |
| Lobectomy | 53 | 54.6 |
| Lobectomy + segmentectomy | 5 | 5.2 |
| Pneumonectomy | 28 | 28.9 |
| Segmentectomy | 5 | 5.2 |
| Total | 97 | 100.0 |

| Procedure | No. of patients | % within procedure |
|-----------|----------------|--------------------|
| Bilobectomy | 6 | 3.6% |
| Lobectomy | 53 | 48.6% |
| Lobectomy + segmentectomy | 5 | 36.9% |
| Pneumonectomy | 28 | 10.8% |
| Segmentectomy | 5 | 100.0% |
| Total | 97 | 100.0% |

| Procedure | No. of patients | % within procedure |
|-----------|----------------|--------------------|
| Bilobectomy | 6 | 3.6% |
| Lobectomy | 53 | 48.6% |
| Lobectomy + segmentectomy | 5 | 36.9% |
| Pneumonectomy | 28 | 10.8% |
| Segmentectomy | 5 | 100.0% |
| Total | 97 | 100.0% |

LSL: left superior lobe; RSL: right superior lobe.

$p = 0.942$ (Pearson’s chi-square). Number of valid cases = 207.
particular complications. Group 1 presented hemorrhagic complications and recurrence, which can be explained by the presence of residual pulmonary cavities after surgery. Group 2 more frequently developed infectious complications, associated with a residual pleural space, bronchopleural fistula and pulmonary tuberculosis sequelae, as discussed earlier. Advances in the surgical technique over the last years has permitted a more frequent indication of pulmonary resection, reserving cavernostomy to patients whose clinical condition does not permit resection surgery. The bronchial stump was not covered with viable tissue in any patient submitted to pulmonary resection.

Table 5 Type of Aspergilloma

| Procedure     | Cavernostomy | No. of patients | Simple | Complex | Total |
|---------------|--------------|-----------------|--------|---------|-------|
| % within procedure |             |                | 10.4%  | 89.6%   | 100.0%|
| Resection     | No. of patients |                | 5      | 88      | 93    |
| % within procedure |             |                | 5.4%   | 94.6%   | 100.0%|
| Total         | No. of patients |                | 16     | 183     | 199   |
| % within Procedure |             |                | 8.0%   | 92.0%   | 100.0%|

*p = 0.196 (Pearson’s chi-square test); p = 0.151 (Fisher’s exact test). Number of valid cases = 199.

Table 6 Preoperative Symptoms

| Preoperative symptom | Group 1 (%) | Group 2 (%) | p   |
|----------------------|-------------|-------------|-----|
| Cough                | 15 (13.5)   | 8 (8.2)     | 0.227|
| Hemoptysis           | 106 (95.5)  | 57 (58.8)   | < 0.001|
| Fever                | 5 (4.5)     | 4 (4.1)     | 0.893|
| Weight loss          | 5 (4.5)     | 5 (5.2)     | 0.827|
| Chest pain           | 8 (7.2)     | 4 (4.1)     | 0.341|
| Dyspnea              | 11 (9.9)    | 5 (5.2)     | 0.199|
| Wheezing             | 5 (4.5)     | 4 (4.1)     | 0.893|
| Others               | 6 (5.4)     | 5 (5.2)     | 0.936|

Table 7 Underlying Diseases

| Underlying disease | Pulmonary abscess | Bronchiectasis | Bronchogenic cyst | TBC | Others | Total |
|--------------------|-------------------|----------------|-------------------|-----|--------|-------|
| Procedure          | Cavernostomy      | No. of patients | 2                 | 2   | 2      | 107   |
|                    | % within procedure |                | 1.9%              | 1.9%| 1.9%   | 100.0%|
| Resection          | No. of patients   |                | 2                 | 1   | 2      | 87    |
|                    | % within procedure |                | 2.1%              | 1.1%| 2.1%   | 100.0%|
| Total              | No. of patients   |                | 4                 | 3   | 4      | 188   |
|                    | % within procedure |                | 2.0%              | 1.5%| 2.0%   | 100.0%|

TBC: tuberculosis sequelae.

Table 8 Type of Fungus

| Type of fungus         | Type of fungus | Aspergillus | Aspergillus fumigatus | Fungus not identified | Others | Total |
|------------------------|----------------|-------------|-----------------------|----------------------|--------|-------|
| Procedure              | Cavernostomy   | No. of patients | 15                    | 37                   | 19     | 6     | 77    |
| % within procedure      |                |              | 19.5%                 | 48.1%                | 24.7%  | 7.8%  | 100.0%|
| Resection              | No. of patients |                | 29                    | 23                   | 14     | 9     | 75    |
| % within procedure      |                |              | 38.7%                 | 30.7%                | 18.7%  | 12.0% | 100.0%|
| Total                  | No. of patients |                | 44                    | 60                   | 33     | 15    | 152   |
| % within procedure      |                |              | 28.9%                 | 39.5%                | 21.7%  | 9.9%  | 100.0%|

*p = 0.029 (Pearson’s chi-square test); p = 0.028 (Fisher’s exact test). Number of valid cases = 152.
because of the view that a residual pleural space is the main cause of empyema and that a bronchopleural fistula is a consequence rather than a cause. Prospective studies should be conducted to clarify this problem.

Groups 1 and 2 were similar in terms of associated diseases. Respiratory diseases were more frequent in group 1, with a difference of borderline significance between groups. A larger number of cases could confirm this difference between groups, showing that patients with respiratory disease were preferentially selected in group 1. Battaglini and colleagues [1] observed that more than half of 15 surgically treated patients had some other severe disease, a fact also reported by other investigators [21] and suggested that these associated medical problems contribute to mortality.

Preoperative respiratory function and age were the two factors differentiating groups 1 and 2 before surgical treatment. Since the two groups were similar in terms of postoperative progression, it seems reasonable to use these two variables to select the surgical therapy for pulmonary aspergilloma. Patients with central lesions not accessible by pneumotomy, with no pleural adhesions, and whose clinical condition does not permit pulmonary resection can be treated by arterial embolization, CT-guided catheter drainage, or intracavitary injection of antifungal drugs. However, these are only alternative therapies which have not been used in the present patients (Figure 1).

In conclusion, the present results suggest that the choice of surgical treatment for aspergilloma should be

![Figure 1 Surgical therapeutic decisions in pulmonary aspergilloma.](http://www.cardiothoracicsurgery.org/content/6/1/129)
based on preoperative respiratory function and age. Older patients with severe preoperative respiratory mal-function and peripheral pulmonary aspergilloma, or lesions accessible by pneumotomy with pleural adhe-sions should be submitted to cavernostomy. Other patients with pulmonary aspergilloma can be treated by pulmonary resection.

Authors’ contributions
JMSC conceived of the study, and participated in its design and coordination. JSR participated in the design of the study. CMSA obtained data and drafted the manuscript. APV obtained data and performed the statistical analysis. FLS obtained data and drafted the manuscript. All authors read and approved the final manuscript.

Competing interests
The authors declare that they have no competing interests.

Received: 16 August 2011 Accepted: 5 October 2011

Published: 5 October 2011

References
1. Battaglini JW, Murry GF, Keagy BA, et al. Surgical management of symptomatic pulmonary aspergilloma. Ann Thorac Surg. 1989, 35:912-6.
2. Chen J, Chang Y, Luh S, et al. Surgical treatment for pulmonary aspergilloma: a 28 year experience. Thorax. 1997, 52:810-3.
3. Gili SC, Gilbert MWP, Frazatto C Jr, et al. Tratamento cirúrgico de “bola fúngica” em leucemia linfóide aguda (LLA). Rev Ass Med Brasil 1992, 36:174-6.
4. Kay PH. Surgical management of pulmonary aspergilloma. Thorax. 1997, 52:753-4.
5. Oakley RE, Petrou M, Coldstraw P. Indications and outcome of surgery for pulmonary aspergilloma. Thorax. 1997, 52:813-5.
6. Shapiro M, Albeeza SM, Mayock RL, et al. Severe hemoptysis associated with pulmonary aspergilloma. Percutaneous intracavitary treatment. J Vasc Interv Radiol. 1999, 10:163-8.
7. Shirakusa T, Ueda H, Saito T, et al. Surgical treatment of pulmonary aspergilloma and Aspergillus empyema. Ann Thorac Surg. 1989, 48:779-82.
8. Park CK, Jeon S. Results of surgical treatment for pulmonary aspergilloma. Eur J Cardiothorac Surg 2002, 21:918-23.
9. Caidi M, Kabini H, Al Azaiz S, El Malouti S, Benosman A. Surgical treatment of pulmonary aspergilloma. 278 cases. Pesez Med 2006, 55:35-1819-24.
10. Lee JG, Lee CY, Park IK, et al. Pulmonary Aspergilloma: A 32-Year History. J Thorac Cardiovasc Surg 2009, 138:820-5.
11. Sagan D, Gozdziuk K, Korobowicz E. Predictive and prognostic value of preoperative symptoms in the surgical treatment of pulmonary aspergilloma. J Surg Res 2010, 163:35-43.
12. Adrèuzo-Harris DJ, Harlin TJ, McGuinness G, et al. Pulmonary aspergilloma and AIDS: A comparison of HIV-infected and HIV-negative individuals. Chest 1997, 111:612-8.
13. Allan A, Sethia B, Turner MA. Recent experience of the treatment of aspergilloma with a surgical stapling device. Thorax 1986, 41:483-4.
14. Butz CR, Zvetina JR, Leininger BJ. Ten-year experience with mycetomas in patients with pulmonary tuberculosis. Chest 1985, 87:356-8.
15. Henderson AH, Deslaurier J, Ritcey EL, et al. Surgery in pulmonary aspergillosis. J Thorac Cardiovasc Surg 1975, 70:1088-94.
16. Henderson AH, Pearson JG. Treatment of bronchopulmonary aspergillosis with observations on the use of natamycin. Thorax 1968, 23:519-23.
17. Jewkes J, Kay PH, Paneth M, et al. Pulmonary aspergilloma: analysis of prognosis in relation to haemoptysis and survey of treatment. Thorax 1983, 38:572-8.
18. Loeckel H. On the transthoracic evacuation of a pulmonary mycetoma using Maurer drainage. Prax Pneumol 1964, 18:757-62.
19. Nwa H, Yarmakawa Y, Fukai I, et al. Subclavian artery branch ligation reduces hemorrhage during resection of pulmonary aspergilloma. Ann Thorac Surg 1995, 59:1234-5.
20. Nucci M, Pulcher W, Spector N, et al. Tratamento de micetoma pulmonar em pacientes neuropênicos. Rev Ass Med Brasil 1995, 19:188.
21. Solt RW, McKeown JJ Jr, Smulders S, et al. The surgical implications of intracavitary mycetomas (fungus balls). J Thorac Cardiovasc Surg 1971, 62:411-22.
22. Belcher JR, Plummer NS. Surgery in broncho-pulmonary aspergillosis. Br J Dis Chest 1960, 54:335-41.
23. Daly RC, Paaroler PO, Piehler IM, et al. Pulmonary aspergilloma. Results of surgical treatment. J Thorac Cardiovasc Surg 1986, 92:981-98.
24. Sagawa M, Sakuma T, Itoh T, et al. Cavernoscopic removal of a fungus ball for pulmonary complex aspergilloma. Ann Thorac Surg 2004, 78:1846-8.
25. Grima R, Krassas A, Bagan P, Badia A, Le Pimpec Barthes F, Riquet M. Treatment of complicated pulmonary aspergillomas with cavernostomy and muscle flap: interest of concomitant limited thoracoplasty. Eur J Cardiothorac Surg 2009, 36:910-3.
26. American Thoracic Society. Medical Section of the American Lung Association: Lung Function Testing. Am Rev Respir Dis 1991, 144:1202-18.
27. Maurer G. Cavernostomy and tamponade of pulmonary cavities with para aminosalicylic acid. Dis Chest 1949, 16:676-80.
28. Kim YT, Kang MC, Sung SW, Kim JH. Good long-term outcomes after surgical treatment of simple and complex pulmonary aspergilloma. Ann Thorac Surg 2005, 79:294-8.
29. Henderson AH. Allergic aspergillosis: review of 32 cases. Thorax 1968, 23:501-12.
30. Sagan D, Gozdziuk K. Surgery for pulmonary aspergilloma in immunocompetent patients: no benefit from adjuvant antifungal pharmacotherapy. Ann Thorac Surg 2010, 89:1603-10.
31. Greenberg AK, Knopp J, Rom WN, et al. Clinical presentation of pulmonary mycetoma in HIV-infected patients. Chest 2002, 122:886-92.
32. Ruz Jr Junior RL, de Oliveira PH, Piotto BL, Muniz FA, Cataneo DC, Cataneo AJ. Surgical treatment of pulmonary aspergilloma. J Bras Pneumol 2010, 36:79-83.
33. Manotta S, Guiffreda E, Tramontano F, et al. Therapeutic approach in pulmonary mycetoma. J Cardiovasc Med 2001, 43:161-5.
34. Walsh TJ, Anassie EJ, Denning DW, et al. Treatment of aspergillosis: clinical practice guidelines of the infectious diseases society of America. CID 2008, 46:327-60.
35. Judson MA, Stevens DA. The treatment of pulmonary aspergilloma. Curr Opin Invest Drugs 2001, 2:1375-7.

Cite this article as: Cesar et al. Cavernostomy x Resection for Pulmonary Aspergilloma: A 32-Year History. Journal of Cardiothoracic Surgery 2011 6:129